Quarterly report pursuant to Section 13 or 15(d)

Organization and Summary of Significant Accounting Policies (Details Narrative)

Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ in Thousands		1 Months Ended		3 Months Ended
	Jan. 09, 2024	Sep. 30, 2023	Aug. 31, 2023	Mar. 31, 2024	Dec. 31, 2023	Jun. 30, 2023	Jul. 31, 2022
Property, Plant and Equipment [Line Items]
Reverse stock split	1-for-20
Cash and cash equivalents				$ 6,200
Money market funds, at carrying value				0	$ 0
Cash, FDIC Insured Amount				$ 250
Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful lives				3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, estimated useful lives				5 years
Rubin [Member]
Property, Plant and Equipment [Line Items]
Aggregate severance payments				$ 400
Pro Neura [Member]
Property, Plant and Equipment [Line Items]
Asset sale description		we entered into an asset purchase agreement (the “Asset Purchase Agreement”) with Fedson, Inc., a Delaware corporation (“Fedson”), for the sale of the ProNeura Assets. Our addiction portfolio consisted of the Probuphine and Nalmefene implant programs. The ProNeura Assets constituted only a portion of our assets. In August 2023, we entered into an Amendment and Extension Agreement (the “Amendment”) to the Asset Purchase Agreement, pursuant to which Fedson agreed to purchase our ProNeura Assets for a purchase price of $2.0 million, consisting of (i) $500,000 in readily available funds, paid in full on the Closing Date, (ii) $500,000 in the form of a promissory note due and payable on October 1, 2023 (the “Cash Note”) and (iii) $1,000,000 in the form of a promissory note due and payable on January 1, 2024 (the “Escrow Note”). We will also be eligible to receive potential milestone payments of up to $50 million on future net sales of the products and certain royalties on future net sales of the products. As further consideration, Fedson assumed all liabilities related to a pending employment claim against us. On the Closing Date, Fedson delivered a written guaranty by a principal of Fedson of all of Fedson’s obligations under both the Cash Note and Escrow Note. The Cash Note included provisions, which Fedson has exercised, allowing Fedson to extend the payment of the Cash Note to November 1, 2023 and again to December 1, 2023 upon payment of $5,000 for each extension. The Cash Note and Escrow Note were paid in December 2023 and January 2024, respectively. We received the funds from the escrow account in February 2024.	we entered into an Amendment to the Asset Purchase Agreement, pursuant to which Fedson agreed to purchase our ProNeura Assets for a purchase price of $2.0 million, consisting of (i) $500,000 in readily available funds, paid in full on the Closing Date, (ii) $500,000 in the form of the Cash Note and (iii) $1,000,000 in the form of the Escrow Note. We will also be eligible to receive potential milestone payments of up to $50 million on future net sales of the products and certain royalties on future net sales of the products. As further consideration, Fedson assumed all liabilities related to a pending employment claim against us. On the Closing Date, Fedson delivered a written guaranty by a principal of Fedson of all of Fedson’s obligations under both the Cash Note and Escrow Note. The Cash Note included provisions, which Fedson has exercised, allowing Fedson to extend the maturity date of the Cash Note to November 1, 2023 and again to December 1, 2023 upon payment of $5,000 for each extension. The Cash Note and Escrow Note were paid in December 2023 and January 2024, respectively. We received the funds from the escrow account in February 2024.
David Lazar And Activist Investing Llc [Member]
Property, Plant and Equipment [Line Items]
Ownership interest by Activist							25.00%
David Lazar [Member]
Property, Plant and Equipment [Line Items]
Ownership interest by Activist						25.00%